Steris (STE) FY2025 10-K Annual Report
Steris (STE) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on May 29, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Steris FY2025 10-K Analysis
Business Overview
- • Core business model: Infection prevention and procedural products and services for healthcare and other industries
- • No new products, services, or segments introduced or highlighted in this filing year
Management Discussion & Analysis
- • Revenue $5.46B, up 6.2% YoY; Healthcare $3.88B (+7.4%), AST $1.04B (+8.9%), Life Sciences $542M (-5.1%)
- • Operating margin Healthcare 25.0% vs 24.1%, AST 44.8% vs 46.1%, Life Sciences 42.3% vs 38.7%
Risk Factors
- • Illinois EO litigation settlement $48.15M expense recognized in FY 2025 indicating ongoing legal risk from state-level enforcement
- • Foreign revenues $1.34B from "Other locations" exposing to currency and geopolitical risks impacting international markets
Steris FY2025 Key Financial MetricsXBRL
Revenue
$5.5B
▲ +6.2% YoY
Net Income
$615M
▲ +62.5% YoY
Gross Margin
44.0%
▲ +84bp YoY
Operating Margin
15.9%
▼ -40bp YoY
Net Margin
11.3%
▲ +390bp YoY
ROE
9.3%
▲ +331bp YoY
Total Assets
$10.1B
▼ -8.3% YoY
EPS (Diluted)
$6.20
▲ +62.7% YoY
Operating Cash Flow
$1.1B
▲ +18.0% YoY
Source: XBRL data from Steris FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Steris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.